Vincenzo Bronte PERSONAL INFORMATION



Istituto Oncologico Veneto IRCCS – Piazza Antenore, 3 – Padua - Italy +39 0498215644

vincenzo.bronte@iov.veneto.it

TATO	DIZ	EXP	וחיד	זמיחו	$c_{\mathbf{r}}$
N/N/ II I	IIK K	HXP	нкі	I IH I'NI	ш н

Scientific Director of the IRCCS Istituto Oncologico Veneto (IOV), Padua, Italy. From March 2022

Tenured Full Professor of Immunology and Head of the Immunology Section From 2011 to 2022

Department of Medicine, Verona University, Italy: ON TEMPORARY LEAVE

Teaching and research activities;

Sector: Immunology, Immunopathology and Tumor immunology

Chief of the Committee that evaluate the high-quality standard in teaching From 2020 to 2021

of Sant' Anna School of Advanced Studies, Pisa, Italy.

From 2018 to 2020 Head of PhD school in "Life and Health Sciences" at University of Verona, Italy.

From 2007 to 2014 Group leader at the Venetian Institute for Molecular Medicine (VIMM)

Via G. Orus 2, 35129, Padua, Italy.

research activities

Sector: Tumor immunology

From 1997 to 2010 Head of the HLA typing laboratory and Oncogenomic Unit

Istituto Oncologico Veneto (IOV), Via Gattamelata 64, 35128 Padua, Italy

Staff scientist - clinical associate at the Istituto Oncologico Veneto (IOV), Via Gattamelata 64 and From 1992 to 2010

Medicine Faculty in Padova University, Padova, Italy

Research and teaching activities

Sector: Immunology, Immunopathology and Tumor immunology

From 1994 to 1996 Exchange scientist

Surgery Branch of the National Cancer Institute, National Institute of Health, Bethesda, USA.

research activities

Sector: Tumor immunology

From 1990 to 1992 Post-doctoral fellow financed by the "Italian Association for Cancer Research" (AIRC).

Istituto Oncologico Veneto (IOV), Via Gattamelata 64, 35128 Padova, Italy

research activities

Sector: Tumor immunology

From Nov 1989 to Dec1989 visiting fellow

Roche laboratories, Basel, Switzerland

- research activities
- <u>Sector</u>: Tumor immunology

From 1988 to 1989

Post-doctoral fellow financed by Fidia Pharmaceuticals - Istituto Oncologico Veneto (IOV), Via Gattamelata 64, 35128 Padova, Italy

- research activities
- Sector: Tumor immunology

EDUCATION AND TRAINING

1992 Specialization (70/70) in Allergy and Clinical Immunology

University of Padova, Italy

Allergy, Autoimmunity, Immunodeficiencies, Transplantation immunity 1988 Medical Degree (M.D.) summa cum laude, University of Padova, Italy. University of Padova, Italy.

WORK ACTIVITIES

Awards

October 2021: award "RECTI-EQUES - PALADINI ITALIANI DELLA SALUTE" for the medical research results, awared by the Associazione Liber, Roma, Italy.

January 2019: Winner of the prize "Veronese dell'anno 2018" for the research achievements in the cancer immunotherapy awarded by the city hall of Verona, Italy.

November 2008: Winner of the Prize "*Guido Venosta*" for oncology researchers awarded by the Italian Foundation for Cancer Research (FIRC).

July 2008: Winner of the prize "*Timone d'argento*" awarded by Lion's Club of Gela, for distinguished Sicilians in the field of art, literature, economy, sport, and science.

April 2007: Winner of the International Prize "Francesco De Luca" for scientific Oncology career awarded by the Accademia Nazionale dei Lincei, Rome, Italy.

Editorial activity

Scientific Journal reviewer: Ad hoc Reviewer for top-rated scientific journals such as Science, Nat Med, Nat Immunol, Nat Rev Immunol, Immunity, Cancer Cell, Nat Comm. Editorial board member of 9 scientific journals Institutional grant panels: Panel Chair/Reviewer for 10 International Funding Agencies including European Research Council, National Institute of Health (USA), French Research Funding Agency and Cancer Research UK.

Invited presentations

Invited speaker in more than 190 international/national congresses.

Patents

- 1. Serafini P, Bicciato S, Caroly J, De la Fuente A, Van Simaeys D, Zilio S, **Bronte V**. (2019). *RNA aptamers and uses thereof*. University of Miami, Florida, US. PCT/US2020/020799
- 2. Serafini P, **Bronte V**. (2017). *Nanoparticle conjugates and uses thereo*. University of Miami, Florida, US. PCT/EP2017/1453.
- 3. **Bronte V**, Ugel S, Fiore A, Sahin U. (2017). *Engineered cells for inducing tolerance*. BioNTECH AG. 674-208 PCT.
- 4. Ugel S, Sandri S, Bobisse S, **Bronte V**. (2015). **Gene sequence encoding a mouse TCR specific** for the human HLA-A2 complex and hTERT865-873 peptide and its use for engineering human T lymphocytes for adoptive cell therapy of cancer. Università di Verona. PCT/IB2016/051510.
- 5. Bronte V, Viola A, Gasco A, Fruttero R, Crosetti M. (2011). Water soluble furoxan derivates having antitumor activity. Humanitas Mirasole Spa, Istituto Oncologico Veneto IRCCS. PCT/IB2011/050743.
- 6. Singh H, Mendrzyk R, Walter S, **Bronte V**, Mandruzzato S. (2010). *Use of myeloid cell biomarkers for diagnosis of cancer*. Immatics Biotechnologies GmbH. 2912919-026000.

- Bronte V, Mandruzzato S. (2009). Myeloid-derived suppressor cells genetated in vitro. Istituto Oncologico Veneto IRCCS. PCT/IB2009700137.
- 8. **Bronte V**, Viola A, Gasco A, Fruttero R, Crosetti M. (2009). *Nitric oxide furoxan derivative compounds endowed with antitumoral activity*. Humanitas Mirasole Spa, Istituto Oncologico Veneto IRCCS. PCT/EP2009/000206.
- Borrello IM, Serafini P, Noonan KA, Bronte V. (2006). PDE5 Inhibitor compositions and methods for immunotherapy. The Johns Hopkins University. PCT/US06/00699.

ADDITIONAL INFORMATION

2011-february 2022

SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

8 graduate students, 15 PhD students and 14 postdoctoral fellows

TEACHING ACTIVITIES

Verona University:

-Immunology and Immunopathology for the Master's degree in Medicine and Surgery – (Jan 2011 – Feb 2022)

-Immunology, PhD School of Life and Health Science, Program in Inflammation, Immunity and Cancer (2014-2022)

-Introduction to Pathology and Immunology, Master's degree in Biotechnology (2011-2017)

ORGANISATION OF SCIENTIFIC MEETINGS

Board of the scientific council organizing committee of 5 national and international meetings

MAJOR COLLABORATIONS

More than 50 national and international collaborators (e.g. Peter Murray, Max Plank Institute of Biochemistry; Ido Amit, Weizmann Institute, Ugur Sahin, BioNtech)

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

American Association for Cancer Research. American Association for Immunologists. Society for Immunotherapy of Cancer. Network Italiano per la BioTerapia dei Tumori. Elected Member of the European Academy for Tumor Immunology.

Publications

total number of publications in peer-review journals: 218

total Impact Factor (IF): 3073,280 (average IF/paper): 14,29

total number of citations: Scopus: 27793, Web of Science: 25623, Google Scholar: 37730.

Hindex: Scopus: 79, Web of Science: 77, Google Scholar: 85 (i10-index: 167)

Top ten representative publications (* last name):

- 1. Bost P. et al. Nat Commun. 2021. PMID: 3367459*
- 2. Marigo I. et al. Cancer Discov. 2020. PMID: 32651166*
- 3. Bronte V. et al. <u>J Clin Invest. 2020</u>. PMID: 32809969
- 4. Fiore A. et al Nat. Commun. 2018. PMID: 30518925*
- 5. Marigo I. et al. Cancer Cell. 2016. PMID: 27622331*
- 6. Bronte V. et al Nat Commun. 2016. PMID: 27381735 (Review)
- 7. Sonda N. et al. Immunity. 2013. PMID: 23809164*
- 8. Ugel S. et al. Cell Rep. 2012. PMID: 22959433*
- 9. Gabrilovich D.I. et al. Nat Rev Immunol. 2012. PMID: 22437938 (Review)*
- 10. Molon B. et al. J Exp Med. 2011. PMID: 21930770*

In the list of Highly Cited Researchers from 2018 to 2021 by "Clarivate Analytics" (147 Immunology scientists in total), world-class researchers with exceptional research performance, multiple highly cited papers that rank in the top 1% by citations for field and year in Web of Science.